

ASX ANNOUNCEMENT

9 June 2023

New Results Show DurAVR™ THV Continues to Demonstrate Sustained Haemodynamics to one year

BRISBANE, Australia and **MINNEAPOLIS, USA**, Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) presents the latest data from the DurAVR™ First-In-Human Study at the TVT Conference. Results show DurAVR™ THV continues to maintain excellent haemodynamic performance as previously reported at one year and 30 day time points.

Preliminary Results:

- 20 patients have been enrolled in the study to date with baseline characteristics as follows: mean age 74.25 years, gender 80% female, mean annulus diameter 22.7 mm, New York Heart Class II and III – 80% and 20%, respectively (classifying the extent of heart failure).
- DurAVR™ THV was successfully implanted in 100% of the cases, with no device-related complications.
- The first 12 patients have completed their one-year follow-up, and results demonstrated sustained haemodynamic performance. Mean Effective Orifice Area (EOA) was reported at 1.98 cm², and Mean Pressure Gradients (MPG) were reported at 9.22 mmHg.
- All study patients (20) have reached their 30-day follow-up, showing results consistent with data previously reported. EOAs saw a 192% increase from 0.69 cm² at baseline to 2.02 cm² at 30 days, while MPG decreased by 84% from 53.34 mmHg to 8.50 mmHg.

Anteris Technologies Chief Executive Officer Wayne Paterson said:

“These results further validate the unique clinical characteristics of DurAVR™ THV and the performance of the novel first-in-class biomimetic design. We continue to be encouraged by the results from the DurAVR™ THV First-In-Human Study and are pleased to see the sustained haemodynamic performance at one year. This supports the ongoing thesis that DurAVR™ THV, a new class of valve, will be an important treatment option for patients in the future.”

Anteris Technologies Chief Medical Officer Chris Meduri, MD, added:

“This is another step forward as we continue building upon the body of evidence that supports the use of DurAVR™ THV in patients with aortic stenosis. We remain pleased with the clinical results and excellent patient outcomes we have seen to date.”

ENDS

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor contact

Deanne Curry

GRACosway

E: investors@anteristech.com

M: +61 414 388 997

Media contact

Nick Howe

GRACosway

nhowe@gracosway.com.au

M: +61 407 183 221

www.anteristech.com

Twitter: [@AnterisTech](https://twitter.com/AnterisTech)

Facebook: www.facebook.com/AnterisTech

LinkedIn: <https://www.linkedin.com/company/anteristech>